Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084214 · ClinicalTrials.gov registry record · Phase 1
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT00084214: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00084214 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084214, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Interventions
- DRUG Paclitaxel
- DRUG STA-4783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084214
The ClinicalTrials.gov registry entry for NCT00084214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00084214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084214 about?
NCT00084214 is a clinical study titled "STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma". This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
What is the current status of trial NCT00084214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00084214?
The interventions under investigation include: Paclitaxel (DRUG), STA-4783 (DRUG).
Who is sponsoring clinical trial NCT00084214?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.